Advanced search
Publication Cover
Acta Cardiologica Volume 70, 2015 - Issue 2
Submit an article Journal homepage
28
Views
6
CrossRef citations to date
0
Altmetric
Articles

Percutaneous closure of inter-atrial communications (atrial septal defect and patent foramen ovale): single-centre experience and mid-term follow-up

Alexander Van De BruaeneHeart Center, Jessa Hospital, Hasselt, Belgium.
, MD, PhD;,
Didier StroobantsHeart Center, Jessa Hospital, Hasselt, Belgium.
, MD; &
Edouard BenitHeart Center, Jessa Hospital, Hasselt, Belgium.Correspondence[email protected]
, MD
Pages 133-140 | Received 29 Sep 2014, Accepted 05 Jan 2015, Published online: 23 May 2017

  • Webb G, Gatzoulis MA. Atrial septal defects in the adult: Recent progress and overview. Circulation 2006; 114:1645–53.
  • Baumgartner H, Bonhoeffer P. De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P. Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E; Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC); Association for European Paediatric Cardiology (AEPC); ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31:2915–57.
  • Eerola A, Pihkala JI, Boldt T, Mattila IP, Poutanen T, Jokinen E. Hemodynamic improvement is faster after percutaneous asd closure than after surgery. Catheter Cardiovasc Intery 2007; 69:432–41; discussion 442.
  • Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Larntz K; Amplatzer Investigators. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: Results of a multicenter nonrandomized trial. J Am Coll Cardiol 2002; 39: 1836–44.
  • Cabanes L, Mas JL, Cohen A, Amarenco P. Cabanes PA, Oubary P. Chedru F, Guerin F, Bousser MG, de Recondo J. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993; 24: 1865–73.
  • LuermansJG, Post MC, Temmerman F, Thijs V, Schonewille WJ, Plokker HW, Suttorp MJ, Budts WI. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine: A prospective observational study. Acta Cardiol 2008; 63:571–7.
  • Post MC, Budts W.The relationship between migraine and right-to-left shunt: Fact or fiction? Chest 2006; 130: 896–901.
  • Post MC, Thijs V, Herroelen L, Budts WI. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 2004; 62: 1439–40.
  • Spencer FA, Lopes LC, Kennedy SA, Guyatt G. Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open 2014; 4: e004282.
  • Riaz IB, Dhoble A, Mizyed A, Hsu CH, Husnain M, Lee JZ, Lotun K, Lee KS. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta-analysis of randomized clinical trials. BMC Cardiovasc Disord 2013; 13: 116
  • Capodanno D, Milazzo G, Vitale L, Di Stefano D, Di Salvo M, Grasso C, Tamburino C. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. Eurolntervention 2014; 9:1342–9.
  • Khan AR, Bin Abdulhak AA, Sheikh MA, Khan 5, Erwin PJ, Tleyjeh I, Khuder 5, Eltahawy EA. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis. JACC Cardiovasc Intent 2013; 6: 1316–23.
  • Agarwal 5, Bajaj NS, Kumbhani DJ, Tuzcu EM, Kapadia SR. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovasc Intent 2012; 5: 777–89.
  • Windecker 5, Wahl A, Chatterjee T, Garachemani A, Eberli FR, Seiler C, Meier B. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000; 101:893–8.
  • Budts W, Legrand V. Peeters A, Thijs V. Management of patent foramen ovale in cryptogenic stroke. Acta Cardiol 2012; 67: 3–9.
  • Boutin C, Musewe NN, Smallhorn JF, Dyck JD, Kobayashi T, Benson LN. Echocardiographic follow-up of atrial septal defect after catheter closure by double-umbrella device. Circulation 1993; 88:621–7.
  • Wang JK, Tsai SK, Wu MH, Lin MT, Lue HC. Short- and intermediate-term results of transcatheter closure of atrial septal defect with the Amplatzer septal occluder. Am Heart J2004; 148: 511–7.
  • Tomar M, Khatri 5, Radhakrishnan 5, Shrivastava S. Intermediate and long-term followup of percutaneous device closure of fossa ovalis atrial septal defect by the Amplatzer septal occluder in a cohort of 529 patients. Ann Pediatr Cardiol 2011; 4: 22–7.
  • Van De Bruaene A, Delcroix M, Pasuclet A, De Backer J, Paelinck B, Morissens M, Budts W. The importance of pulmonary artery pressures on late atrial arrhythmia in transcatheter and surgically closed ASD type secundum. Int J Cardiol 2011; 152:192–5.
  • Van De Bruaene A, Moons P. Belmans A, Post MC, Luermans JG, Delcroix M, Pasquet A, De Backer J, Paelinck B, Morissens M, Budts W. Predictive model for late atrial arrhythmia after closure of an atrial septal defect. Int J Cardiol 2013; 164:318–22.
  • Gatzoulis MA, Freeman MA, Siu SC, Webb GD, Harris L. Atrial arrhythmia after surgical closure of atrial septal defects in adults. N Engl J Med 1999; 340:839–46.
  • Van De Bruaene A, La Gerche A, Prior DL, Voigt J-U, Delcroix M, Budts W. Pulmonary vascular resistance as assessed by bicycle stress echocardiography in patients with atrial septal defect type secundum. Circ Cardiovasc Imaging 2011; 4: 237–45.
  • Correa R, Zahn E, Khan D. Mid-term outcomes of the Helex septal occluder for percutaneous closure of secundum atrial septal defects. Congenit Heart Dis 2013; 8:428–33.
  • Marchese N, Pacilli MA, Inchingolo V, Fanelli R, Loperfido F, Vigna C. Residual shunt after percutaneous closure of patent foramen ovale with Amplatzer occluder devices - influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study. Eurolntervention 2013; 9:382–8.
  • Braun M, Gliech V, Boscheri A, Schoen 5, Gahn G, Reichmann H, Haass M, Schraeder R, Strasser RH.Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J 2004; 25:424–30.
  • Matsumura K, Gevorgyan R, Mangels D, Masoomi R, Mojadidi MK, Tobis J. Comparison of residual shunt rates in five devices used to treat patent foramen ovale. Catheter Cardiovasc Intery 2014; 84:455–63.
  • Hammerstingl C, Bauriedel B, Stusser C, Momcilovic D, Tuleta I, Nickenig G, Skowasch D. Risk and fate of residual interatrial shunting after transcatheter closure of patent foramen ovale: a long term follow up study. Eur J Med Res 2011; 16:13–9.
  • von Bardeleben RS, Richter C, Otto J, Himmrich L, Schnabel R, Kampmann C, Rupprecht HJ, Marx J, Hommel G, Munzel T, Horstick G. Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: difference in occlusion systems and influence of atrial septum aneurysm. Int J Cardiol 2009; 134: 33–41.
  • Greutmann M, Greutmann-Yantiri M, Kretschmar 0, Senn 0, Roffi M, Jenni R, Luescher TF, Eberli FR. Percutaneous PFO closure with Amplatzer PFO occluder: Predictors of residual shunts at 6 months follow-up. Congenit Heart Dis 2009; 4:252–7.
  • Sorensen SG, Spruance SL, Smout R, Horn S. Transcranial Doppler quantification of residual shunt after percutaneous patent fora-men ovale closure: correlation of device efficacy with intracardiac anatomic measures. J Intery Cardiol 2012; 25: 304–12.
  • Lee JY, Song JK, Song JM, Kang DH, Yun SC, Kang DW, Kwon SU, Kim JS. Association between anatomic features of atrial septal abnormalities obtained by omni-plane transesophageal echocardiography and stroke recurrence in cryptogenic stroke patients with patent foramen ovale. Am J Cardiol 2010; 106: 129–34.
  • Rudolph V, Augustin J, Hofmann T, Hamm CW, Meinertz T, K8ster R, Baldus 5, Franzen O. Predictors of recurrent stroke after percutaneous closure of patent foramen ovale. Eurolntervention 2014; 9:1418–22.
  • Wahl A, Krumsdorf U, Meier B, Sievert H, Ostermayer 5, Billinger K, Schwerzmann M, Becker U, Seiler C, Arnold M, Mattle HP, Windecker S.Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. J Am Coll Cardiol 2005; 45: 377–80.
  • LuermansJG, Budts W, Ten Berg JM, Plokker HW, Suttorp MJ, Post MC. Comparison of outcome after patent foramen ovale closure in older versus younger patients. Eurolntervention 2011; 7:209–15.
  • Puricel 5, Arroyo D, Goy JJ, Praz F, Palhais N, Wahl A, Stauffer JC, Togni M, Berger A, Meier B, Cook S. A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION). Eurolntervention 2014; pii: 20130124–01.
  • Spies C, Reissmann U, Timmermanns I, Schrader R. Comparison of contemporary devices used for transcatheter patent foramen ovale closure. J Invasive Cardiol 2008; 20:442–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.